Biotech | April 04, 2022
Merck expands manufacturing facility in Virginia to increase HPV vaccine supply
Supply increase to help meet growing global demand
Supply increase to help meet growing global demand
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Subscribe To Our Newsletter & Stay Updated
